PCM
DMK

Palisade Capital Management’s DMK Pharmaceuticals Corporation Common Stock DMK Stock Holding History

Palisade Capital Management’s Portfolio DMK Stock Details DMK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-286
Closed -$127K – 493
2014
Q1 		$127K Buy
+286
New +$130K ﹤0.01% 445

Other funds holding DMK

GP
Grow Partners San Diego, California $4.81M AUM 7.86% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
SM
Scoggin Management New York $1.04B AUM 232.32% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Palisade Capital Management's DMK Position: Q2 2014 in Review

Palisade Capital Management sold out of DMK Pharmaceuticals Corporation Common Stock (DMK) in Q2 2014, closing a stake of 286 shares — an estimated $127K sold.

Palisade Capital Management first reported a position in DMK in Q1 2014 and held it in 1 quarter. The position peaked at $127K in Q1 2014. 20 funds tracked by Wall St. Rank hold DMK as of Q2 2014.

  • Palisade Capital Management reported no remaining DMK Pharmaceuticals Corporation Common Stock position as of Q2 2014 after selling out during the quarter.
  • Palisade Capital Management sold 286 DMK Pharmaceuticals Corporation Common Stock shares in Q2 2014, an estimated $127K.
  • Palisade Capital Management first reported a position in DMK Pharmaceuticals Corporation Common Stock in Q1 2014 and held it in 1 quarter.
  • Palisade Capital Management's DMK Pharmaceuticals Corporation Common Stock position peaked at $127K in Q1 2014.
  • 20 funds tracked by Wall St. Rank held DMK Pharmaceuticals Corporation Common Stock as of Q2 2014.

Based on Palisade Capital Management's 13F filing for Q2 2014, filed 6 Aug 2014.